Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss shot shows promise in Mid-Stage trial

NCT ID NCT07020884

Disease control Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental injection called ZT002 in 303 adults who were overweight or obese. Participants received either the drug or a placebo for 24 weeks. The main goal was to see how much weight they lost and whether they achieved 5%, 10%, or 15% weight loss. The trial is now complete, and results will help determine if ZT002 is safe and effective for weight management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

303 people

The number who actually took part.

Started

Aug 2024

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years. * BMI ≥28 kg/m², or 24 kg/m2 ≤ BMI \< 28 kg/m2 with at least one comorbidity (pre-diabetes, hypertension, hyperlipidemia, fatty liver, obstructive sleep apnoea syndrome due to overweight, weight-bearing joint pain, etc.) * Weight change is not more than 5% with diet and exercise control alone within 3 months prior to screening. Exclusion Criteria: * Previous diagnosis of diabetes; or HbA1c ≥ 6. 5% or fasting blood glucose ≥ 7.0 mmol/L at screening. * Have used medicines or treatments that affect weight within 3 months prior to screening. * History of acute or chronic pancreatitis. * Personal or family (parents, children, and siblings) history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type II (MEN2). * History of definite mental disease within 2 years prior to screening or prior suicidal tendency or suicidal behavir; or PHQ-9 scale score is ≥ 15 at screening; or C-SSRS questionnaire is either class 4 or 5 at screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight or obesity

Contacts and locations

Locations

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212000, China

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, 250000, China

  • First Hospital of Qinhuangdao

    Qinhuangdao, Hebei, 066000, China

  • Genertec Liaoyou Gem Flower Hospital

    Panjin, Liaoning, 124000, China

  • Handan First Hospital

    Handan, Hebei, 056002, China

  • Hebei Petro China Cental Hospital

    Langfang, Hebei, 065000, China

  • Luoyang Third People's Hospital

    Luoyang, Henan, 471002, China

  • Nanjing Jiangning Hospital

    Nanjing, Jiangsu, 210000, China

  • Peking University First Hospital

    Beijing, 100044, China

  • Peking University People's Hospital

    Beijing, 100044, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, 471000, China

  • The First Affiliated of Nanyang Medical College

    Nanyang, Henan, 473000, China

  • The Fourth Affiliated Hospital Harbin Medical University

    Harbin, Heilongjiang, 150001, China

  • Tonghua Central Hospital

    Tonghua, Jilin, 134000, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, 710000, China

  • Zibo Municipal Hospital

    Zibo, Shandong, 255400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.